Article
The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.
Oncogene - 26 Jul 2007
Minami Y, Shimamura T, Shah K, LaFramboise T, Glatt K A, Liniker E, Borgman C L, Haringsma H J, Feng W, Weir B A, Lowell A M, Lee J C, Wolf J, Shapiro G I, Wong K-K, Meyerson M, Thomas R K
Abstract excerpt
Mutations in the ERBB2 gene were recently found in approximately 2% of primary non-small cell lung cancer (NSCLC) specimens; however, little is known about the functional consequences and the relevance to responsiveness to targeted drugs for most of these mutations. Here, we show that the major lung cancer-derived ERBB2 mutants, including the most frequent mutation, A775insYVMA, lead to oncogenic transformation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.